Detected ·
Neurosterix
$105MSeries B
Neurosterix, a Geneva biotech spun out of Addex Therapeutics, closed a USD 105 million Series B from an unnamed syndicate of life science investors to advance NTX-253, an oral M4 positive allosteric modulator for schizophrenia, into Phase 2.
- Website
- www.neurosterix.com
- linkedin.com/company/102894167
- Amount
- $105 000 000 USD
- Stage
- Series B
- Event
- Funding round
- Detected
- 2026-11-12 15:16:10 UTC
- Signal ID
- 66357a61-733a-448e-81a5-5b3e4c0045fb
As the API returns it
{
"id": "66357a61-733a-448e-81a5-5b3e4c0045fb",
"created_at": "2026-11-12T15:16:10.491017Z",
"company_name": "Neurosterix",
"company_website_url": "www.neurosterix.com",
"company_linkedin_url": "https://www.linkedin.com/company/102894167",
"event_type": "funding",
"funding_amount": 105000000,
"funding_currency": "USD",
"funding_stage": "series_b",
"message": "*Neurosterix, a Geneva biotech spun out of Addex Therapeutics, closed a USD 105 million Series B from an unnamed syndicate of life science investors to advance NTX-253, an oral M4 positive allosteric modulator for schizophrenia, into Phase 2.*"
}